Literature DB >> 22189570

Sensory neuronopathy in patients harbouring recessive polymerase γ mutations.

Nichola Z Lax1, Roger G Whittaker, Philippa D Hepplewhite, Amy K Reeve, Emma L Blakely, Evelyn Jaros, Paul G Ince, Robert W Taylor, Peter R W Fawcett, Doug M Turnbull.   

Abstract

Defects in the mitochondrial DNA replication enzyme, polymerase γ, are an important cause of mitochondrial disease with ∼25% of all adult diagnoses attributed to mutations in the POLG gene. Peripheral neuronopathy is often part of the clinical syndrome and can represent the most disabling feature. In spite of this, the molecular mechanisms underlying the neuronopathy remain to be elucidated and treatment strategies are limited. In the present study, we use a combined approach comprising clinical, electrophysiological, neuropathological and molecular genetic investigations to unravel the mechanisms underpinning peripheral neuronopathy in autosomal recessive polymerase γ-related disease. Electrophysiological assessments documented a dorsal root ganglionopathy in all 11 cases. Of the 11 cases, eight also showed changes consistent with motor fibre loss. Detailed neuropathological investigation of two patients confirmed the electrophysiological findings, revealing atrophy of posterior columns and striking neuronal cell loss from the dorsal root ganglia, which was accompanied by severe mitochondrial biochemical abnormalities involving respiratory chain complexes I and IV due to clonally-expanded mitochondrial DNA deletions and a significant reduction in mitochondrial DNA copy number in affected neurons. We propose that the respiratory chain defects, secondary to mitochondrial DNA deletion and depletion, are likely to be responsible for pathology observed in the dorsal root ganglion and the sensory ganglionopathy documented electrophysiologically.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22189570      PMCID: PMC3267986          DOI: 10.1093/brain/awr326

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  26 in total

1.  The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases.

Authors:  Charalampos Tzoulis; Bernt A Engelsen; Wenche Telstad; Jan Aasly; Massimo Zeviani; Synnøve Winterthun; Gianfrancesco Ferrari; Jan H Aarseth; Laurence A Bindoff
Journal:  Brain       Date:  2006-04-25       Impact factor: 13.501

2.  Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene.

Authors:  Rita Horvath; Gavin Hudson; Gianfrancesco Ferrari; Nancy Fütterer; Sofia Ahola; Eleonora Lamantea; Holger Prokisch; Hanns Lochmüller; Robert McFarland; V Ramesh; Thomas Klopstock; Peter Freisinger; Fabrizio Salvi; Johannes A Mayr; Rene Santer; Marketa Tesarova; Jiri Zeman; Bjarne Udd; Robert W Taylor; Douglass Turnbull; Michael Hanna; Doreen Fialho; Anu Suomalainen; Massimo Zeviani; Patrick F Chinnery
Journal:  Brain       Date:  2006-04-18       Impact factor: 13.501

3.  Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions.

Authors:  G Van Goethem; B Dermaut; A Löfgren; J J Martin; C Van Broeckhoven
Journal:  Nat Genet       Date:  2001-07       Impact factor: 38.330

4.  SANDO: two novel mutations in POLG1 gene.

Authors:  Miguel Fernandes Gago; M J Rosas; Joana Guimarães; Mariana Ferreira; Laura Vilarinho; Lígia Castro; Stirling Carpenter
Journal:  Neuromuscul Disord       Date:  2006-08-21       Impact factor: 4.296

5.  POLG, but not PEO1, is a frequent cause of cerebellar ataxia in Central Europe.

Authors:  Julia Schicks; Matthis Synofzik; Claudia Schulte; Ludger Schöls
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

6.  Sensory ataxic neuropathy with dysarthria and ophthalmoparesis (SANDO) in late life due to compound heterozygous POLG mutations.

Authors:  Michael D Weiss; Russell P Saneto
Journal:  Muscle Nerve       Date:  2010-06       Impact factor: 3.217

7.  Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement.

Authors:  J Betts; E Jaros; R H Perry; A M Schaefer; R W Taylor; Z Abdel-All; R N Lightowlers; D M Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2006-08       Impact factor: 8.090

8.  Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma.

Authors:  Massimiliano Filosto; Michelangelo Mancuso; Yutaka Nishigaki; Jacklyn Pancrudo; Yadollah Harati; Clifton Gooch; Ami Mankodi; Lydia Bayne; Eduardo Bonilla; Sara Shanske; Michio Hirano; Salvatore DiMauro
Journal:  Arch Neurol       Date:  2003-09

9.  Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR.

Authors:  Langping He; Patrick F Chinnery; Steve E Durham; Emma L Blakely; Theresa M Wardell; Gillian M Borthwick; Robert W Taylor; Douglass M Turnbull
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

10.  Novel POLG1 mutations associated with neuromuscular and liver phenotypes in adults and children.

Authors:  J D Stewart; S Tennant; H Powell; A Pyle; E L Blakely; L He; G Hudson; M Roberts; D du Plessis; D Gow; L D Mewasingh; M G Hanna; S Omer; A A Morris; R Roxburgh; J H Livingston; R McFarland; D M Turnbull; P F Chinnery; R W Taylor
Journal:  J Med Genet       Date:  2009-03       Impact factor: 6.318

View more
  27 in total

Review 1.  Alpers-Huttenlocher syndrome.

Authors:  Russell P Saneto; Bruce H Cohen; William C Copeland; Robert K Naviaux
Journal:  Pediatr Neurol       Date:  2013-03       Impact factor: 3.372

Review 2.  Inherited mitochondrial genomic instability and chemical exposures.

Authors:  Sherine S L Chan
Journal:  Toxicology       Date:  2017-07-26       Impact factor: 4.221

Review 3.  Sensory Neuronopathies.

Authors:  Allison Crowell; Kelly G Gwathmey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-23       Impact factor: 5.081

4.  The role of astrocytes in seizure generation: insights from a novel in vitro seizure model based on mitochondrial dysfunction.

Authors:  Felix Chan; Nichola Z Lax; Caroline Marie Voss; Blanca Irene Aldana; Shuna Whyte; Alistair Jenkins; Claire Nicholson; Sophie Nichols; Elizabeth Tilley; Zoe Powell; Helle S Waagepetersen; Ceri H Davies; Doug M Turnbull; Mark O Cunningham
Journal:  Brain       Date:  2019-02-01       Impact factor: 13.501

5.  Neurotoxicity of cytarabine (Ara-C) in dorsal root ganglion neurons originates from impediment of mtDNA synthesis and compromise of mitochondrial function.

Authors:  Ming Zhuo; Murat F Gorgun; Ella W Englander
Journal:  Free Radic Biol Med       Date:  2018-04-23       Impact factor: 7.376

Review 6.  Recessive cerebellar and afferent ataxias - clinical challenges and future directions.

Authors:  Marie Beaudin; Mario Manto; Jeremy D Schmahmann; Massimo Pandolfo; Nicolas Dupre
Journal:  Nat Rev Neurol       Date:  2022-03-24       Impact factor: 42.937

7.  A Targeted Mutation Disrupting Mitochondrial Complex IV Function in Primary Afferent Neurons Leads to Pain Hypersensitivity Through P2Y1 Receptor Activation.

Authors:  Rory Mitchell; Graham Campbell; Marta Mikolajczak; Katie McGill; Don Mahad; Sue M Fleetwood-Walker
Journal:  Mol Neurobiol       Date:  2019-01-28       Impact factor: 5.590

8.  The impact of pathogenic mitochondrial DNA mutations on substantia nigra neurons.

Authors:  Amy Reeve; Martin Meagher; Nichola Lax; Eve Simcox; Philippa Hepplewhite; Evelyn Jaros; Doug Turnbull
Journal:  J Neurosci       Date:  2013-06-26       Impact factor: 6.167

9.  Dissecting the mechanisms underlying the accumulation of mitochondrial DNA deletions in human skeletal muscle.

Authors:  Georgia Campbell; Kim J Krishnan; Marcus Deschauer; Robert W Taylor; Doug M Turnbull
Journal:  Hum Mol Genet       Date:  2014-04-15       Impact factor: 6.150

10.  Microangiopathy in the cerebellum of patients with mitochondrial DNA disease.

Authors:  Nichola Z Lax; Ilse S Pienaar; Amy K Reeve; Philippa D Hepplewhite; Evelyn Jaros; Robert W Taylor; Raj N Kalaria; Doug M Turnbull
Journal:  Brain       Date:  2012-05-09       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.